Cipla receives USFDA approval for Albendazole Tablets in USA

Cipla has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Albendazole Tablets in strength of 200mg. The drug Albendazole Tablets 200mg is AB-rated generic therapeutic equivalent version of Impax Laboratories, Albenza. It is an anthelmintic drug indicated for use in treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

According to industrial estimates, the US sales of approximately $99 million for the 12 month period ending July 2018.

Be the first to comment

Leave a Reply

Your email address will not be published.